Inborn Errors of Macronutrient Metabolism

Inborn errors of macronutrient metabolism are inherited disorders in which a genetic defect impairs an enzyme or transporter in a carbohydrate, lipid, or amino acid pathway. The block causes substrates to accumulate or essential products to become deficient, and the resulting biochemical disturbance gives rise to the clinical features of the disorder.

Definition

Inborn errors of macronutrient metabolism are monogenic disorders in which a deficient or defective enzyme or transporter disrupts a carbohydrate, lipid, or amino acid pathway, producing toxic accumulation of substrates, deficiency of products, or impaired energy supply.

Scope

This entry orients the reader to the general logic of inborn errors affecting the three macronutrient classes — the consequences of an enzyme block, the broad disease categories, and how these conditions are detected — with named examples such as phenylketonuria, glycogen storage diseases, and fatty acid oxidation defects. It is a reference and educational overview, not a diagnostic or treatment resource.

Key concepts

• Enzyme or transporter deficiency
• Substrate accumulation and product deficiency
• Aminoacidopathies
• Glycogen storage diseases
• Fatty acid oxidation defects
• Urea cycle disorders
• Newborn screening

Mechanisms

Each disorder reflects the failure of a single step in a metabolic pathway. Garrod's concept of a 'one gene, one enzyme' block explains how a missing enzyme can cause disease in three broad ways: by allowing a substrate or upstream metabolite to accumulate to toxic levels, by depriving the cell of a needed product, or by interrupting energy production. In phenylketonuria, for example, deficient phenylalanine hydroxylase lets phenylalanine accumulate; in glycogen storage diseases, defects in glycogen synthesis or breakdown impair glucose availability; in fatty acid oxidation defects, the body cannot mobilize fat for energy during fasting; and in urea cycle disorders, ammonia disposal fails. The pattern of accumulated and deficient metabolites determines the biochemical signature used to recognize each condition.

Clinical relevance

These disorders illustrate how a defined biochemical lesion produces disease and are the rationale for newborn screening programmes that detect treatable conditions early. The entry conveys mechanism and category as background knowledge; specific diagnosis and management of any individual are matters for qualified clinical genetics and metabolic specialists and are outside the scope of this reference.

Epidemiology

Individually most inborn errors of metabolism are rare, but collectively they form a substantial group of inherited disease, which is why many countries screen newborns for a panel of treatable disorders such as phenylketonuria.

Evidence & guidelines

Condition-specific clinical guidelines exist for individual disorders, such as the American College of Medical Genetics and Genomics guideline for phenylalanine hydroxylase deficiency; such guidance is referenced to show how these disorders are managed in practice and is not a substitute for specialist clinical care.

History

Archibald Garrod introduced the idea of 'inborn errors of metabolism' in the early twentieth century, proposing that certain diseases stem from inherited blocks in specific chemical reactions — a concept that anticipated the gene-enzyme relationship. The later development of newborn screening, building on Robert Guthrie's blood-spot test for phenylketonuria, turned many of these disorders into conditions detectable before symptoms appear.

Key figures

• Archibald Garrod
• Jean-Marie Saudubray
• Robert Guthrie

Seminal works

• saudubray-2018
• vockley-2014

Frequently asked questions

What is an inborn error of metabolism?

It is an inherited disorder in which a genetic defect impairs a single enzyme or transporter in a metabolic pathway, so that substrates build up, needed products are lacking, or energy production is disrupted.

Why are many of these disorders screened for at birth?

Several inborn errors, such as phenylketonuria, can cause serious harm if untreated but are manageable when caught early, so newborn screening aims to detect treatable conditions before symptoms develop.